Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19

Benzinga · 1d ago
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $18 to $19.